[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dda68f62026281b2e72f3c65ce0d2020e8ec9fc10c6abdf4db9135cef7988394",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731688860,
      "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "id": 131417098,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dda68f62026281b2e72f3c65ce0d2020e8ec9fc10c6abdf4db9135cef7988394"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform Recommendation",
    "summary": "Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform Recommendation",
    "url": "https://finnhub.io/api/news?id=fefc80f0312e79cb6d691551c34b083bf0beefb55784395dffd6e9ccc9adff4d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731685883,
      "headline": "Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform Recommendation",
      "id": 131372954,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fefc80f0312e79cb6d691551c34b083bf0beefb55784395dffd6e9ccc9adff4d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer",
    "summary": "PRINCETON, N.J., November 15, 2024--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite....",
    "url": "https://finnhub.io/api/news?id=13c0d89e1336388d30522a6627eb701883df22c0362a90b2be3948b93249d63d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731676980,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer",
      "id": 131371524,
      "image": "https://s.yimg.com/ny/api/res/1.2/C9QpOD26mLQwuDUGyicuZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xNjU-/https://media.zenfs.com/en/business-wire.com/e6fe328e12a07487ba23d02214e0f434",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 15, 2024--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite....",
      "url": "https://finnhub.io/api/news?id=13c0d89e1336388d30522a6627eb701883df22c0362a90b2be3948b93249d63d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors",
    "summary": "PRINCETON, N.J., November 15, 2024--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer....",
    "url": "https://finnhub.io/api/news?id=20b33de1877bae1724f6f7583d58ec58b2d1dd01447a996b8910dc9a84d94522",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731671940,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors",
      "id": 131371525,
      "image": "https://s.yimg.com/ny/api/res/1.2/2vHAlmC_a56EieFxwTIiSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xNjU-/https://media.zenfs.com/en/business-wire.com/3eba96e274f2d893dbb2e1063f16aed9",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 15, 2024--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer....",
      "url": "https://finnhub.io/api/news?id=20b33de1877bae1724f6f7583d58ec58b2d1dd01447a996b8910dc9a84d94522"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: positive opinion from CHMP for Opdivo",
    "summary": "Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo in combination with Yervoy for...",
    "url": "https://finnhub.io/api/news?id=8ea48878919be876981d127078128d7ec69f860d14c86c765c088eaaad41b315",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731662836,
      "headline": "Bristol Myers: positive opinion from CHMP for Opdivo",
      "id": 131370367,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo in combination with Yervoy for...",
      "url": "https://finnhub.io/api/news?id=8ea48878919be876981d127078128d7ec69f860d14c86c765c088eaaad41b315"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug",
    "summary": "By Colin Kellaher Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a...",
    "url": "https://finnhub.io/api/news?id=684ec4811a05c76606ec5e406ebf2657c790d956e59ea9fe1e86af898dfbea43",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731657013,
      "headline": "Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug",
      "id": 131368808,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a...",
      "url": "https://finnhub.io/api/news?id=684ec4811a05c76606ec5e406ebf2657c790d956e59ea9fe1e86af898dfbea43"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: positive opinion for repotrectinib in U",
    "summary": "Bristol Myers Squibb announces that it has received a positive opinion from the CHMP of the European Medicines Agency for its repotrectinib in the treatment of ROS1-positive advanced non-small cell...",
    "url": "https://finnhub.io/api/news?id=f7e2dc6b5b20f3df153754788598db433b07923ad54235c8c4eccb0734f9ceb3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731656187,
      "headline": "Bristol Myers: positive opinion for repotrectinib in U",
      "id": 131368538,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces that it has received a positive opinion from the CHMP of the European Medicines Agency for its repotrectinib in the treatment of ROS1-positive advanced non-small cell...",
      "url": "https://finnhub.io/api/news?id=f7e2dc6b5b20f3df153754788598db433b07923ad54235c8c4eccb0734f9ceb3"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Value Discovery Fund Q3 2024 Review",
    "summary": "On the positive side, the fund benefited from favorable stock picking in industrials, health care and information technology, as well as an underweight in the last of these three sectors.",
    "url": "https://finnhub.io/api/news?id=1aa51c77728b92cd901727e88b352448301e76a8f6d2d4980bd341be7418f764",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731653100,
      "headline": "Fidelity Value Discovery Fund Q3 2024 Review",
      "id": 131367643,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "On the positive side, the fund benefited from favorable stock picking in industrials, health care and information technology, as well as an underweight in the last of these three sectors.",
      "url": "https://finnhub.io/api/news?id=1aa51c77728b92cd901727e88b352448301e76a8f6d2d4980bd341be7418f764"
    }
  }
]